Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants With Advanced or Metastatic Select Solid Tumors

NCT07085091 is registered in ClinicalTrials.gov with ALX Oncology Inc. as lead sponsor.

NCT NCT07085091
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07085091 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants With Advanced or Metastatic Select Solid Tumors
Lead sponsor
ALX Oncology Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
August 18, 2025
Completion date
December 31, 2027
Enrollment
170 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

colo-rectal cancer, crc (colorectal cancer), escc, esophageal squamous cell carcinoma (escc), head and neck cancer, hnscc, nsclc (advanced non-small cell lung cancer)